Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Receptor-mediated Endocytosis01:38

Receptor-mediated Endocytosis

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Journal of hematology & oncology·2026
Same author

Cross-priming underlies the efficacy of antibody-drug conjugates and immunotherapy combinations.

Trends in immunology·2026
Same author

Monomethyl-auristatin E-based anti-CD137 (4-1BB) antibody drug conjugates are not suitable tools to deplete activated T lymphocytes.

Immunobiology·2026
Same author

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Journal for immunotherapy of cancer·2026
Same author

Engineering and improving anti-CTLA-4 checkpoint inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer.

The Journal of clinical investigation·2026

Related Experiment Video

Updated: May 10, 2026

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation
08:24

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation

Published on: May 22, 2017

High-density lipoproteins delivering interleukin-15.

Maria C Ochoa1, Ignacio Melero, Pedro Berraondo

  • 1Division of Hepatology and Gene Therapy; Center for Applied Medical Research, and University Clinic; University of Navarra, Pamplona; Navarra, Spain.

Oncoimmunology
|June 5, 2013
PubMed
Summary

This study explores using lipoproteins as drug carriers. Fusing apolipoprotein A-I with interleukin-15 (IL-15) targets it to high-density lipoproteins (HDLs) for enhanced therapeutic delivery.

Keywords:
Sushi domainapolipoprotein AIhigh-density lipoproteininterleukin 15

More Related Videos

High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Related Experiment Videos

Last Updated: May 10, 2026

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation
08:24

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation

Published on: May 22, 2017

High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Area of Science:

  • Biotechnology
  • Drug Delivery Systems
  • Protein Engineering

Background:

  • Circulating lipoproteins offer potential as stable and well-distributed therapeutic carriers.
  • Cytokines and hormones can be effectively delivered using engineered protein constructs.

Purpose of the Study:

  • To investigate the use of apolipoprotein A-I (ApoA-I) fused with interleukin-15 (IL-15) as a targeted therapeutic delivery system.
  • To enhance the bioactivity of IL-15 by targeting it to high-density lipoproteins (HDLs).

Main Methods:

  • Constructing a fusion protein combining ApoA-I with IL-15.
  • Developing triple fusion proteins incorporating the IL-15 receptor α domain for enhanced IL-15 trans-presentation.

Main Results:

  • The ApoA-I-IL-15 fusion protein successfully targets IL-15 to HDLs.
  • Triple fusions demonstrate potential for enhanced IL-15 bioactivity through improved trans-presentation.

Conclusions:

  • Engineered lipoproteins, specifically ApoA-I-IL-15 fusions, represent a promising strategy for targeted cytokine and hormone delivery.
  • Further development of these constructs could lead to improved therapeutic efficacy and reduced side effects.